Patents Assigned to Otsuka Pharmaceuticals Co., Ltd.
  • Equol-containing extract, method for production thereof, method for extraction of equol, and equol-containing food
    Patent number: 10681930
    Abstract: The present invention relates to an extract obtained by extracting useful components containing equal from an equol-containing fermented soybean hypocotyl, and to a method for producing the same. The present invention makes it possible to efficiently obtain useful components containing equol from the fermented soybean hypocotyl by subjecting an equol-containing fermented soybean hypocotyl to extraction using an ethanol aqueous solution as an extractant. The present invention reduces the content of saponin, which causes an unpleasant taste, by sequentially subjecting the equal-containing fermented soybean hypocotyl to extraction using an ethanol aqueous solution and ethanol, while efficiently extracting equol and glycitein.
    Type: Grant
    Filed: November 9, 2012
    Date of Patent: June 16, 2020
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Michiaki Tominaga, Takao Taki, Toshiaki Matsumoto, Izumi Hanya, Takuma Imada, Kunihiko Matsuoka, Takuya Kishimoto, Yuko Uchiyama, Hiromasa Tsuneishi, Machiko Tsuji, Tania Valdes-Gonzalez, Kentaro Tadano, Kyoko Kameda
  • INJECTABLE PREPARATION
    Publication number: 20200179517
    Abstract: An object of the present invention is to provide a storage-stable injectable preparation comprising a composition comprising a poorly soluble drug as an active ingredient and a dispersion medium. Another object of the present invention is to provide a compact, lightweight prefilled syringe by filling a syringe with the injectable preparation. The present invention provides an injectable preparation comprising a composition comprising a poorly soluble drug, a dispersion medium, and a specific suspending agent, the composition having a viscosity of 40 pascal-seconds or more in at least one point in the shear rate range of 0.01 to 0.02 s?1 and having a viscosity of 0.2 pascal-seconds or less in at least one point in the shear rate range of 900 to 1,000 s?1, as measured.
    Type: Application
    Filed: February 7, 2020
    Publication date: June 11, 2020
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Daiki KANEKO, Takakuni MATSUDA, Yusuke HOSHIKA
  • Method of Evaluating Nutriture
    Publication number: 20200182856
    Abstract: An aspect of the disclosure provides a method of evaluating the nutriture of a subject, comprising (1) calculating the ratio of the 13CO2 amount to the unlabeled CO2 amount or total CO2 amount in an expired air sample obtained from the subject to which a 13C-labeled amino acid was administered; and (2) comparing the ratio with a reference value to evaluate the nutriture. Another aspect of the disclosure provides a composition comprising a 13C-labeled amino acid for evaluating the nutriture of a subject.
    Type: Application
    Filed: November 24, 2017
    Publication date: June 11, 2020
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Makoto INADA, Keiko KAWATA, Kimiyoshi SUDOU
  • 5-METHYL-6-PHENYL-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVE
    Publication number: 20200181092
    Abstract: The present invention provides an agent for treating malignant tumor, comprising a compound of formula (1): wherein R1 to R4 are hydrogen atom, halogen, or etc., Y is optionally-substituted alkylene group or etc.
    Type: Application
    Filed: February 12, 2020
    Publication date: June 11, 2020
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Takahiro KATOH, Masatoshi Iida, Yuki Terauchi, Kazuya Yamaguchi, Toshiyuki Hirose, Fumiharu Yokoyama, Hikaru Nishimori, Yutaka Obuchi, Hiroshi Nabeshima, Emiri Takaki
  • OINTMENT CONTAINING AN OXAZOLE COMPOUND
    Publication number: 20200171006
    Abstract: An ointment is provided. The ointment stably comprises an oxazole compound that has specific inhibitory activity against PDE4 and that is represented by the following formula (11). The ointment can be efficiently absorbed into the skin.
    Type: Application
    Filed: February 5, 2020
    Publication date: June 4, 2020
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Yoshihiro MURAKAMI, Hitoshi MATSUSHITA, Kengo MATSUMOTO, Minoru OKADA, Yohei YUKI, Noriyuki KOYAMA, Naohiko KANAI
  • INJECTABLE FORMULATION
    Publication number: 20200163960
    Abstract: An object of the present invention is to provide a sustained-release injectable preparation which is in a medication administration form that can provide the effect of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one for a prolonged period of time, the preparation releasing a therapeutically effective amount of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one for at least one week. The present invention provides an injectable preparation containing 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof as an active ingredient, which releases the active ingredient in such a manner that its blood concentration is maintained for at least one week.
    Type: Application
    Filed: January 28, 2020
    Publication date: May 28, 2020
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Tetsuya SATO, Takuya MINOWA, Yusuke HOSHIKA, Hidekazu TOYOFUKU
  • DUAL CHAMBER PREFILLABLE SYRINGE AND ARIPIPRAZOLE FILLED IN SYRINGE
    Publication number: 20200155764
    Abstract: A dual chamber prefillable syringe (100) includes: a cylinder (10) which has a bypass portion (11); a hub luer-lock (20); a front stopper (30); a middle stopper (40) which seals a preparation (S) together with the front stopper (30); an end stopper (50) which seals a solvent (L) together with the middle stopper (40); a finger grip (60); and a plunger rod (70) which is connected to the end stopper from the rear end side. A female screw portion (64) which is screwed around the axis line is formed on an inner circumferential surface of the finger grip (60), and a male screw portion (73) which is able to be screwed to the female screw portion is formed on an outer circumferential surface of the plunger rod (70).
    Type: Application
    Filed: November 15, 2019
    Publication date: May 21, 2020
    Applicants: ARTE CORPORATION, OTSUKA PHARMACEUTICAL CO. LTD.
    Inventors: Makoto KAKIUCHI, Seiji SHIMAZAKI, Yasuhiko TAKESHIMA, Shogo HIRAOKA, Tadayoshi MAESAKA
  • Method for activating helper T cell
    Patent number: 10654892
    Abstract: The present invention relates to a method for activating helper T cells, which includes the step of activating helper T cells by adding a WT1 peptide to antigen presenting cells, wherein the WT1 peptide has the ability to bind to any MHC class II molecule of an HLA-DRB1*0101 molecule, an HLA-DRB1*0401 molecule, an HLA-DRB1*0403 molecule, an HLA-DRB1*0406 molecule, an HLA-DRB1*0803 molecule, an HLA-DRB1*0901 molecule, an HLA-DRB1*1101 molecule, an HLA-DRB3*0202 molecule, an HLA-DRB4*0101 molecule, an HLA-DPB1*0201 molecule or an HLA-DPB1*0301 molecule, and the like.
    Type: Grant
    Filed: October 4, 2011
    Date of Patent: May 19, 2020
    Assignees: International Institute of Cancer Immunology, Inc., OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Haruo Sugiyama, Shinji Sogo, Masayoshi Sato, Ryuki Kitamoto, Yoshihiro Goto
  • DIHYDRATE OF BENZOTHIOPHENE COMPOUND OR OF A SALT THEREOF, AND PROCESS FOR PRODUCING THE SAME
    Publication number: 20200140424
    Abstract: An object of the present invention is to provide a compound that can be used as a more superior therapeutic agent for central nervous system diseases. The present invention provides a dihydrate of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl) butoxy]-1H-quinolin-2-one or of a salt thereof, and a process for producing the same.
    Type: Application
    Filed: September 9, 2019
    Publication date: May 7, 2020
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Hiroshi YAMASHITA, Tetsuya SATO, Takuya MINOWA, Yusuke HOSHIKA, Hidekazu TOYOFUKU, Tatsuya YAMAGUCHI, Masahiro SOTA, Shuuji KAWANO, Takayuki NAKAMURA, Ryohei ETO, Takuma IKEBUCHI, Kei MORIYAMA, Nobuaki ITO
  • METHOD FOR PRODUCING PROCESSED FOOD
    Publication number: 20200128858
    Abstract: Provided is a method for producing a processed food, in which the generation of a sulfur smell or the imparting of an unpleasant flavor like an accumulated sulfur smell is suppressed. [Means for Resolution] Provided is a method for producing a processed food in which the generation of a sulfur smell is suppressed, including the following steps (A) and (B): (A) a step of bringing a transglutaminase and/or a reducing sugar into contact with a solid food material containing a protein as a main nutritional component; and (B) a step of subjecting the food material after the step (A) to a heat sterilization treatment.
    Type: Application
    Filed: July 3, 2017
    Publication date: April 30, 2020
    Applicant: EN Otsuka Pharmaceutical Co., Ltd.
    Inventor: Yuji HONMA
  • Microspheres having core/shell structure
    Patent number: 10632079
    Abstract: Disclosed are microspheres having a core/shell structure and a spherical shape, wherein (a) the core comprises solid-state aripiprazole, and (b) the shell coats all or most of the surface of the core, and the shell comprises a biodegradable polymer; a process for producing the microspheres; and an injectable aqueous suspension formulation containing the microspheres; and the like.
    Type: Grant
    Filed: June 9, 2008
    Date of Patent: April 28, 2020
    Assignee: Otsuka Pharmaceuticals Co., Ltd.
    Inventor: Shogo Hiraoka
  • Injectable formulation
    Patent number: 10624889
    Abstract: An object of the present invention is to provide a sustained-release injectable preparation which is in a medication administration form that can provide the effect of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one for a prolonged period of time, the preparation releasing a therapeutically effective amount of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one for at least one week. The present invention provides an injectable preparation containing 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof as an active ingredient, which releases the active ingredient in such a manner that its blood concentration is maintained for at least one week.
    Type: Grant
    Filed: September 12, 2017
    Date of Patent: April 21, 2020
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Tetsuya Sato, Takuya Minowa, Yusuke Hoshika, Hidekazu Toyofuku
  • Cyanotriazole compounds
    Patent number: 10626095
    Abstract: This invention relates to a cyanotriazole compound represented by the formula (1): wherein each symbols are defined in the specification, or a salt thereof. The compound or a salt thereof stimulates the citric acid cycle activity and/or improves hyperglycemia with less side effects, and excellent safety, and therefore, it is useful for treating and/or preventing diseases or disorders on which citric acid cycle activation and/or improvement of hyperglycemia has a prophylactic and/or therapeutic effect, for example, diabetes, impaired glucose tolerance, insulin resistance, diabetic complications, obesity, dyslipidemia, hepatic steatosis, atherosclerosis and/or cardiovascular disease, as well as diseases or disorders that would benefit from stimulating energy expenditure.
    Type: Grant
    Filed: July 16, 2014
    Date of Patent: April 21, 2020
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Seiji Sato, Satoshi Matsuda, Chiharu Matsumura, Motohiro Itotani, Toshio Shinohara, Shigekazu Fujita, Yohji Sakurai, Kuninori Tai, Tae Fukushima, Naohide Kanemoto, Takashi Okamoto
  • 5-methyl-6-phenyl-4,5-dihydro-2H-pyridazin-3-one derivative
    Patent number: 10611731
    Abstract: The present invention provides an agent for treating malignant tumor, comprising a compound of formula (1): wherein R1 to R4 are hydrogen atom, halogen, or etc., Y is optionally-substituted alkylene group or etc.
    Type: Grant
    Filed: March 2, 2017
    Date of Patent: April 7, 2020
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Takahiro Katoh, Masatoshi Iida, Yuki Terauchi, Kazuya Yamaguchi, Toshiyuki Hirose, Fumiharu Yokoyama, Hikaru Nishimori, Yutaka Obuchi, Hiroshi Nabeshima, Emiri Takaki
  • Method of treating disorders caused by reduced neurotransmission of serotonin, norephnephrine or dopamine
    Patent number: 10603331
    Abstract: A heterocyclic compound represented by the general formula (1) or a salt thereof: wherein m, l, and n respectively represent an integer of 1 or 2; X represents —O— or —CH2—; R1 represents hydrogen, a lower alkyl group, a hydroxy-lower alkyl group, a protecting group, or a tri-lower alkylsilyloxy-lower alkyl group; R2 and R3, which are the same or different, each independently represent hydrogen or a lower alkyl group; or R2 and R3 are bonded to form a cyclo-C3-C8 alkyl group; and R4 represents an aromatic group or a heterocyclic group, wherein the aromatic or heterocyclic group may have one or more arbitrary substituent(s).
    Type: Grant
    Filed: August 30, 2018
    Date of Patent: March 31, 2020
    Assignee: Otsuka Pharmaceutical Co., Ltd.
    Inventors: Nobuaki Ito, Hirofumi Sasaki, Kuninori Tai, Tomoichi Shinohara
  • METHOD OF TREATING BIPOLAR I AND II DISORDERS
    Publication number: 20200093823
    Abstract: The present invention relates to a method of treating a patient suffering from a disorder of the central nervous system associated with 5-HT1A receptor subtype, comprising as an active ingredient a carbostyril derivative or a salt thereof represented by the formula (1) wherein the carbon-carbon bond between 3- and 4-positions in the carbostyril skeleton is a single or a double bond.
    Type: Application
    Filed: November 26, 2019
    Publication date: March 26, 2020
    Applicant: Otsuka Pharmaceutical Co., Ltd.
    Inventors: Shaun Jordan, Tetsuro Kikuchi, Katsura Tottori, Tsuyoshi Hirose, Yasufumi Uwahodo
  • PACKAGED MEDICINE
    Publication number: 20200093700
    Abstract: Provided is packaged medicine capable of inhibiting deterioration of electrodes over a long period of time and reliably transmitting a signal after ingestion even when a long period of time has elapsed since production to ingestion. The packaged medicine includes a solid medicine including drug powder and a micro-device, a container provided with a solid medicine accommodating space accommodating the solid medicine therein, and inert gas encapsulated in the solid medicine accommodating space. The micro-device includes two electrodes with mutually different ionization tendencies and a transmitter operable to transmit a signal using electromotive force generated when the electrodes come in contact with electrolyte.
    Type: Application
    Filed: May 1, 2018
    Publication date: March 26, 2020
    Applicant: Otsuka Pharmaceutical Co., Ltd.
    Inventors: Kazuma YOKOI, Kenzo KASHIHARA, Kenta YAMAMOTO, Takahiro SONOKI, Shohei YAMADA
  • Ointment containing an oxazole compound
    Patent number: 10588893
    Abstract: An ointment is provided. The ointment stably comprises an oxazole compound that has specific inhibitory activity against PDE4 and that is represented by the following formula (11). The ointment can be efficiently absorbed into the skin.
    Type: Grant
    Filed: December 27, 2016
    Date of Patent: March 17, 2020
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Yoshihiro Murakami, Hitoshi Matsushita, Kengo Matsumoto, Minoru Okada, Yohei Yuki, Noriyuki Koyama, Naohiko Kanai
  • OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION
    Publication number: 20200078340
    Abstract: The present invention provides a oxazole compound represented by Formula (1), or a salt thereof: wherein R1 is an aryl group which may have one or more substituents; R2 is an aryl group or a nitrogen atom-containing heterocyclic group each of which may have one or more substituents; and W is a divalent group represented by —Y1-A1- or —Y2—C(?O)— wherein Y1 is a group such as —C(?O)—, A1 is a group such as a lower alkylene group, and Y2 is a group such as a piperazinediyl group. The oxazole compound has a specific inhibitory action against phosphodiesterase 4.
    Type: Application
    Filed: November 12, 2019
    Publication date: March 12, 2020
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Minoru OKADA, Masaya KATO, Norifumi SATO, Tetsuyuki UNO, Hideki KITAGAKI, Junpei HARUTA, Hidetaka HIYAMA, Tomonori SHIBATA
  • Piperazine-substituted benzothiophenes for treatment of mental disorders
    Patent number: RE48059
    Abstract: The present invention provides a heterocyclic compound represented by the general formula (1): The compound of the present invention has a wide treatment spectrum for mental disorders including central nervous system disorders, no side effects and high safety.
    Type: Grant
    Filed: November 16, 2017
    Date of Patent: June 23, 2020
    Assignee: Otsuka Pharmaceutical Co., Ltd.
    Inventors: Hiroshi Yamashita, Nobuaki Ito, Shin Miyamura, Kunio Oshima, Jun Matsubara, Hideaki Kuroda, Haruka Takahashi, Satoshi Shimizu, Tatsuyoshi Tanaka, Yasuo Oshiro, Shinichi Taira